Suzhou Myxobio Biotechnology Co., Ltd. Secures Tens of Millions of RMB in Angel Funding to Pioneer Myxobacteria-Based Biocontrol Solutions for Intractable Plant Diseases

Recently, Suzhou Myxobio Biotechnology Co., Ltd. (hereinafter referred to as “Myxobio”) officially announced the completion of its angel financing round amounting to tens of millions of yuan. This round was jointly invested by Shicui Capital, Innocore Fund, and Tuofeng Ventures, with Ruohua Capital serving as the long-term exclusive financial advisor. The raised funds will be primarily allocated to scaling up the manufacturing processes for myxobacteria-based product pipelines, expanding commercial channels, and developing applications for several intractable diseases currently lacking effective treatments, thereby injecting new momentum into green agricultural disease control.

The global agricultural crop protection sector is currently facing multiple challenges: rising resistance to chemical pesticides, increasingly stringent environmental regulations, and escalating consumer demands for food safety. Consequently, the development of green and highly efficient biological control solutions has become an industry consensus and an urgent necessity. Among these challenges, persistent plant diseases such as fusarium wilt in melons and fruits, fire blight, and soft rot act as the “cancers” of the plant world. Characterized by high contagion, severe damage, and significant difficulty in control, these diseases have long lacked effective management strategies, resulting in annual economic losses amounting to hundreds of billions of dollars globally and creating a substantial market gap with unmet needs. Myxobio precisely targets this industry pain point by deeply engaging in the field of biological control, committed to providing breakthrough biological solutions for these “terminal illnesses” of plants.

Certain species of myxobacteria possess robust capabilities for predating on living microorganisms. Their biocontrol mechanisms differ from those of existing commercial biocontrol microbial strains, offering significant application potential in the field of biological control. However, the application of myxobacteria has long been constrained by two global challenges: the difficulty in isolating highly efficient strains and the hurdles in achieving large-scale industrialization. As a result, their value has yet to be fully realized.

Professor Cui Zhongli, founder of Myxobio, has dedicated over 30 years to the field of microbiology. He serves as the Chief Scientist for a National Key R&D Program project and has received prestigious honors, including the Second Prize of the National Science and Technology Progress Award and the Second Prize of the Ministry of Education’s Technological Invention Award. Professor Cui’s team has published more than 100 papers in top-tier international journals such as Nature Communications, ISME J, and Microbiome. They have uniquely elucidated the mechanism by which myxobacteria prey on plant-pathogenic fungi, demonstrating profound academic expertise and keen industry insight.

Leveraging its team’s solid expertise in microbiology and innovative approaches to industrialization, Myxobio has built a globally leading high-efficiency platform for the isolation and screening of myxobacterial strains, establishing a comprehensive resource library of high-performance functional myxobacterial strains. Meanwhile, it has pioneered breakthroughs in multi-ton-scale fermentation and formulation processes for myxobacteria worldwide, becoming the only startup team globally to achieve industrial-scale production of myxobacteria, thereby thoroughly overcoming key technical challenges in this field.

Leveraging its leading myxobacteria technology platform and unique prevention and control mechanisms, Myxobio has developed highly efficient, safe, and eco-friendly specialized bio-agents to tackle a variety of "incurable" intractable agricultural diseases, safeguarding agricultural production with robust technical strength.

Targeting the “invisible killers” of high-value Phalaenopsis orchids—Southern Blight and Black Head Disease—Myxobio has launched specialized myxobacterial formulations. The Southern Blight-specific formulation proactively establishes a preventive microbial ecosystem at the source, nipping problems in the bud and fortifying the health defense line for the Phalaenopsis industry. Meanwhile, the Black Head Disease-specific formulation demonstrates remarkable curative efficacy, enabling complete resolution of disease symptoms within two weeks and helping Phalaenopsis orchids regain healthy growth vigor.

Fire blight, the second-most significant quarantine disease globally, can rapidly spread throughout an entire orchard once an outbreak occurs. Mild cases result in a 30%–50% reduction in yield, while severe cases can lead to total crop failure, causing devastating losses for fruit growers. Myxobio’s specialized myxobacterial formulation for pear trees demonstrated remarkable efficacy in large-scale field trials in Xinjiang in 2025, enabling severely infected pear trees to recover within two weeks. This breakthrough offers a novel solution to address this persistent challenge in fire blight management for the fruit tree industry.

The successful completion of this funding round marks Myxobio’s entry into a new phase of rapid growth. Moving forward, the company will continue to deepen the iterative development of its myxobacteria process technologies, focus on more intractable diseases with limited treatment options, and accelerate the R&D of efficient, eco-friendly solutions. Simultaneously, it will advance its market deployment and channel expansion, leveraging innovative biotechnology to address critical pain points in agricultural disease control and prevention, thereby contributing Chinese wisdom and strength to global sustainable agriculture and food security.

Suzhou Myxobio Biotechnology Co., Ltd., as the world’s sole biomanufacturing enterprise leveraging a myxobacteria platform, remains steadfast in its core mission to effectively address agricultural diseases with no available treatments. Deeply committed to green biological control, the company empowers sustainable agricultural development through breakthrough technologies and high-quality products, striving to become a global leader in plant health.